Introduction {#s1}
============

Depression is the leading cause of disability worldwide and has an average prevalence of approximately 20% ([@CIT0032]). Current pharmacotherapy for depression acts primarily on the monoamine neurotransmitter systems, modulating the synaptic availability of neurotransmitters like serotonin and noradrenaline ([@CIT0011]). However, only about 60--70 percent of depressed patients achieve full remission, indicating a need for development of alternative antidepressant drugs ([@CIT0019]; [@CIT0056]). In the last decade, a number of studies have associated aberrations in epigenetic modifications, like DNA methylation and histone modifications, with psychiatric disorders, including depression ([@CIT0068]). Drugs affecting the epigenome have thus gained increased attention with regard to their potential therapeutic efficacy ([@CIT0029]; [@CIT0053]). Histone deacetylase inhibitors (HDACis), for instance, have been extensively used in animal models and have shown antidepressant-like effects ([@CIT0013]).

Sodium butyrate (NaB) is an established and widely-used HDACi ([@CIT0009]; [@CIT0061]) that exerts antidepressant-like effects while simultaneously increasing the levels of brain-derived neurotrophic factor (BDNF; [@CIT0060]). BDNF is a neurotrophin that promotes neurogenesis and neuroplasticity, and there is strong evidence for its involvement in the neurobiology of psychiatric disorders like depression ([@CIT0002]). The *Bdnf* gene is highly conserved between humans and rodents, and has multiple epigenetically-controlled messenger RNA (mRNA) isoforms that are formed by different 5' untranslated exons splicing to a common 3' protein-coding exon ([@CIT0001]; [@CIT0006]). One of the best-characterized *Bdnf* mRNA isoforms is the one driven by the promoter of exon 4 (*Bdnf* P4; [@CIT0041]; [@CIT0069]; [@CIT0040]). The expression of *Bdnf* P4 correlates well with the expression of total brain BDNF and is highly responsive to neuronal activity and antidepressant drug treatment ([@CIT0071]; [@CIT0016]; [@CIT0017]). *Bdnf* P4 was also shown to be regulated both by chromatin modifications through the actions of HDACs and by DNA methylation through the action of DNA methyltransferases (DNMTs; [@CIT0041]).

While most studies using NaB have focused on its effects on histone acetylation, there are also findings showing that it affects DNA methylation ([@CIT0014]; [@CIT0014]; [@CIT0012]; [@CIT0004]; [@CIT0005]; [@CIT0010]; [@CIT0003]; [@CIT0015]; [@CIT0046]; [@CIT0059]; [@CIT0025]; [@CIT0063]). DNA methylation in vertebrates has been known to involve the DNMT-catalyzed addition of methyl groups to cytosine residues (5mC), but the mechanisms underlying DNA demethylation have been debated for a long time ([@CIT0072]). However, recently it was shown that hydroxylation of 5mC by ten-eleven translocation (TET) proteins leads to the formation of 5-hydroxymethylcytosine (5hmC), which can then mediate active DNA demethylation ([@CIT0035]; [@CIT0066]; [@CIT0026]). Interestingly, brain levels of tet methylcytosine dioxygenase 1 (TET1) were also found to correlate positively with *Bdnf* expression ([@CIT0026]; [@CIT0031]).

In the present report, we hypothesized a mechanism of action for NaB as an enhancer of gene-specific demethylation in the brain, possibly mediated by NaB's epigenetic effects on the transcription of DNMTs and/or TETs. For the purpose of this study, and to examine NaB's antidepressant efficacy in parallel, we used a genetic rat model of depression (the Flinders Sensitive Line \[FSL\]) and its controls (the Flinders Resistant Line \[FRL\]). The FSL rats exhibit depression-like behavioral characteristics, including psychomotor retardation and sleep disturbances, as well as emotional memory impairments and dysfunctional regulation of glutamate transmission ([@CIT0050]; [@CIT0018]; [@CIT0022]). The FSL have also been successfully used to study both pharmacological and non-pharmacological interventions with epigenetic and antidepressant-like effects, including the use of acetylating agents to epigenetically modulate *Grm2* ([@CIT0047]), selective serotonin reuptake inhibitors to epigenetically modulate *p11* ([@CIT0043]) and physical activity to epigenetically modulate *Npy* ([@CIT0042]).

Methods {#s2}
=======

Animals, Drug Administration, and Behavioral Testing {#s3}
----------------------------------------------------

Male FRL and FSL rats (3 months old) were obtained from the breeding stables at the Centre for Psychiatric Research, Aarhus University, Aarhus, Denmark. NaB, diluted in saline, was administered intraperitoneally (i.p.) to FRL (FRL-NaB; n = 7) and FSL (FSL-NaB; n = 7), in parallel with saline (vehicle \[Veh\]) i.p. injections (FRL-Veh; n = 7; FSL-Veh; n = 7). Both agents were administered chronically, twice a day for 23 days, with an injection volume of 1ml/kg body weight and a dosage of 0.4g NaB/kg of body weight. To assess antidepressant-like behavior, a behavioral despair test (the Porsolt forced swimming test \[FST\]) was used, which has an excellent predictive validity for antidepressant agents ([@CIT0055]). FST experiments were performed as previously described ([@CIT0020]). In brief, FRL and FSL rats were placed in transparent cylinders (24cm diameter, 60cm height) filled with 40cm water at a temperature of 25±1 ˚C for 5min and the immobility time was scored by a person blind to the treatment conditions. The rats were sacrificed 24h after the FST and the brains were harvested and kept at -80 ˚C until shipment to the Karolinska Institutet for brain dissection according to the method of [@CIT0021]. For the purpose of the molecular analyses, the PFC was separated in two parts: left and right. The left part was homogenized and divided into equal amounts for DNA and RNA extraction. The right part of the PFC was used for protein analyses. All experiments were approved by the Danish National Committee for Ethics in Animal Experimentation and the Ethical Committee for Protection of Animals at the Karolinska Institutet.

DNA/RNA Extraction and Reverse Transcription {#s4}
--------------------------------------------

DNA was extracted using the QIAamp DNA Mini Kit (Qiagen GmbH) and total RNA was isolated using the miRNeasy Mini Kit (Qiagen) following treatment with DNase I (Qiagen) to digest contaminating DNA. Complementary DNA (cDNA) was synthesized using the SuperScript III First-Strand Synthesis System for RT-PCR (Invitrogen; Life Technologies) according to the manufacturer's protocol. In brief, equal amounts of RNA were random-hexamer primed at 25°C for 10min, followed by an incubation with SuperScript III RT at 50°C for 50min, and termination of the reaction at 85°C for 5min. DNA/complementary DNA was stored at -20^o^C and RNA at -80^o^C until further processing.

Gene Expression {#s5}
---------------

Quantitative real-time polymerase chain reaction (qRT-PCR) was used to assess mRNA expression of target and reference genes. All qRT-PCR amplifications were performed in triplicate using Power SYBR Green (Applied Biosystems; Life Technologies) on an ABI PRISM 7900 HT Sequence Detection System (Applied Biosystems), with the following conditions: 95°C for 10min, followed by 40 repeats of 95°C for 15sec and 60°C for 1min, and a final dissociation stage to monitor amplification specificity. Target genes included *Tet1*, tet methylcytosine dioxygenase 2 (*Tet2*), tet methylcytosine dioxygenase 3 (*Tet3*), DNA (cytosine-5) methyltransferase 1 (*Dnmt1*), DNA (cytosine-5) methyltransferase 3 alpha (*Dnmt3a*), and brain-derived neurotrophic factor (*Bdnf*). Two reference genes were used for normalization purposes (glyceraldehyde-3-phosphate dehydrogenase \[*Gapdh*\] and cyclophilin A \[*Ppia*\]). Relative quantification of gene expression was calculated using the qBase software (version 1.3.4; [@CIT0028]). The 5'-to-3' primer sequences were: *Tet1* forward (Fw): CCGGTCGCCAAGTGGGTGAT; *Tet1* reverse (Rv): GGTCCACACGCTCACGAACCA; *Tet2* Fw: TACCGTACAGCCACCCAAAC; *Tet2* Rv: CGT GACT GGAACTGC TCACT; *Tet3* Fw: GGACTTCTGTGCCCACGCCC; *Tet3* Rv: TCAGGGTGCAGACCACAGTGC; *Dnmt1* Fw: GGCCAGCCCCAT GAAACGCT; *Dnmt1* Rv: GGG GCGTCCAGGTTGCTTCC; *Dnmt3a* Fw: TCCAACATGAGCCGCTTGGCG; *Dnmt3a* Rv: GGTGGC GGATGACTGGCACG; *Bdnf* P4 Fw: GCTG CCT TGATGTTTACTTTGA; *Bdnf* P4 Rv: GCAACCGAAGTATGAAATAACC; total *Bdnf* Fw: GGCCCAACGAAGAAAACCAT; total *Bdnf* Rv: AGCATCACCC GGGAAGTGT; *Gapdh* Fw: TCGGTGTGAACGGATTTGGCCG; *Gapdh* Rv: CCGTTGAACTTGCCGTGGGT; *Ppia* Fw: GGCTGATGGC GAGCCCTTGG; and *Ppia* Rv: CGTGTGAAGTCACCACCCTGGC. *Dnmt3b* mRNA levels were not assessed since we have previously found this gene not to be abundantly expressed (Ct values \> 35) in the prefrontal cortex region of FSL/FRL animals ([@CIT0043]).

Protein Expression {#s6}
------------------

Genes showing a difference on the mRNA level were also tested for changes on the protein levels using a modified Western blot protocol, based on [@CIT0038]. Briefly, following sample homogenization and centrifugation, lysates were boiled for 5min and protein concentrations were measured using the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific Inc.) and equal amounts of protein (20 µg for TET1, 20 µg for BDNF, and 60 µg for DNMT1) were loaded on a NuPAGE Novex 4--12% Bis-Tris Gel (Invitrogen). The separated protein was transferred to Amersham Hybond ECL Nitrocellulose Membrane (GE Healthcare UK Limited) overnight at 4°C, and then blocked with 5% nonfat milk for 1h at room temperature. Immunoblotting was performed overnight at 4°C with a polyclonal rabbit anti-methylcytosine dioxygenase 1 (TET1) antibody (1:1 000 dilution; 09--872, Millipore), a monoclonal rabbit anti-BDNF antibody (1:1 000 dilution; ab108319, Abcam), or with a monoclonal rabbit anti- DNMT1 antibody (1:1 000 dilution; No.5119, Cell Signaling Technology) and, separately, with a mouse monoclonal anti-β-actin antibody (1:10 000; A5316, Sigma-Aldrich). After washing, the membrane for detecting TET1, BDNF, or DNMT1 was incubated with HRP-linked goat anti-rabbit secondary antibody (1:60 000 for TET1, 1:50 000 for BDNF, and 1:100 000 for DNMT1; Santa Cruz Biotechnology) and the membrane for detecting β-actin was incubated with HRP-linked goat anti-mouse secondary antibody (1:20 000; Santa Cruz Biotechnology) for 50min at room temperature. Finally, immunoreactive bands were visualized with the Amersham ECL Plus Western Blotting Detection System (GE Healthcare), exposed to Amersham Hyperfilm ECL (GE Healthcare), and optical densities were quantified using the NIH ImageJ software (1.47 version). TET1, BDNF, and DNMT1 expression levels were normalized to the expression of β-actin and the data are presented as relative quantifications.

DNA Hydroxymethylation and Methylation Analyses {#s7}
-----------------------------------------------

Global levels of DNA hydroxymethylation (5hmC)---i.e., the average percent of genomic DNA cytosines that are hydroxymethylated at the 5^th^ carbon---were assessed using the Quest 5-hmC DNA ELISA Kit (Zymo Research Corp.) according to the manufacturer's protocol. All samples were processed in duplicate and control DNAs were used to generate a standard curve for quantitation of the 5hmC percentage. To measure gene-specific 5hmC levels at the *Bdnf* P4 promoter, the Hydroxymethyl Collector Kit (Active Motif Inc.) was used according to the manufacturer's sonication protocol. Gene-specific levels of DNA methylation (5mC) at the *Bdnf* P4 promoter were determined using the MethylCollector Ultra kit (Active Motif) again according to the manufacturer's sonication protocol. Samples and inputs from the 5hmC and 5mC assays were analyzed in triplicate with qRT-PCR, using Power SYBR Green (Applied Biosystems) on an ABI PRISM 7900 HT Sequence Detection System (Applied Biosystems) under the same conditions described in the gene expression section. Data are presented as % input, which is calculated as 100 x 2^-ΔCt^, where ΔCt = the average Ct value of the input triplicate minus the average Ct value of the sample triplicate. The 5'-to-3' primer sequences capturing part of the *Bdnf* P4 promoter (-67 nucleotides to +99; referenced from P4's transcription start site) were: *Bdnf* P4 promoter Fw: TCGAGGCAGAGGAGGTATCA and *Bdnf* P4 promoter Rv: TCTA GGCAGA GAC TGGGAGA.

Statistical Analyses {#s8}
--------------------

Data in bar graphs are presented as mean values ± 1 standard error of the mean (SEM). The Shapiro-Wilk and Levene's tests were used for assessing the normality of the data and the homogeneity of the variance, respectively. Group differences were analyzed using one-way ANOVA and significant effects were further investigated with the Fisher's least significant difference (LSD) post-hoc analysis for multiple comparisons. The Pearson's R correlation test was used to assess the correlation between levels of 5hmC and 5mC. Differences were regarded as statistically significant when *p* \< 0.05. The number of animals used in each experiment, in addition to potential outliers, is denoted in the figure legends. Outliers were excluded from the statistical analyses. All analyses were performed using IBM SPSS Statistics 22 (IBM Corporation).

Results {#s9}
=======

Sodium Butyrate Exerts Antidepressant-Like Effects {#s10}
--------------------------------------------------

As a first step in our study we assessed behavioral despair in FSL/FRL, both with Veh and NaB treatment, using the forced swimming test. In line with previous results, FSL-Veh rats showed increased immobility compared to FRL-Veh (ANOVA, *p* = 0.0022; FSL-Veh vs. FRL-Veh, Fisher's LSD, post-hoc *p* = 0.0014; [Figure 1](#F1){ref-type="fig"}). Significantly, chronic NaB-treatment rescued the FSL depression-like phenotype; there was a pronounced decrease in immobility time, which reached the levels similar to those of both Veh and NaB-treated FRL ([Figure 1](#F1){ref-type="fig"}).

![The behavioral despair test (Porsolt forced swimming test) was used in our study to evaluate the antidepressant-like effects of NaB. In line with the use of FSL as a genetic model of depression-like states, Veh-treated FSL animals showed significantly higher immobility compared to the FRL-Veh. Treatment with NaB significantly decreased the immobility time in the FSL but had no effects in the FRL strain. Data are presented as means ± SEM. n = 7 animals per group. \*\**p* \< 0.01.](ijnppy_pyu032_f0001){#F1}

Aberrant TET1 Levels in the Prefrontal Cortex of FSL {#s11}
----------------------------------------------------

Next, in order to address the hypothesis that NaB's antidepressant-like effects may be related to changes in the expression of enzymes regulating DNA methylation in the prefrontal cortex, we measured mRNA levels of candidate genes involved in DNA hydroxymethylation and methylation (*Tet1, Tet2, Tet3, Dnmt1,* and *Dnmt3a*). Among all the candidate genes tested, only *Tet1* showed a difference between vehicle-treated FRL and FSL. More specifically, TET1 mRNA levels were decreased in FSL-Veh compared to FRL-Veh (ANOVA, *p* = 0.0038; FSL-Veh vs. FRL-Veh, Fisher's LSD, post-hoc *p* = 0.039; [Figure 2A](#F2){ref-type="fig"}). NaB treatment, which was previously shown to exert antidepressant-like effects, was associated with an upregulation of *Tet1* mRNA in the FSL-NaB group (FSL-Veh vs. FSL-NaB, Fisher's LSD, post-hoc *p* = 0.0067; [Figure 2A](#F2){ref-type="fig"}). Western blot experiments confirmed that the *Tet1* group-differences observed on the mRNA levels were also present on the protein levels (ANOVA, *p* = 0.0029; FSL-Veh vs. FRL-Veh, Fisher's LSD, post-hoc *p* = 0.0012; FSL-Veh vs. FSL-NaB, Fisher's LSD, post-hoc *p* \< 0.001; [Figure 2B](#F2){ref-type="fig"}). NaB treatment, though less significantly, was also associated with downregulated *Dnmt1* mRNA levels in the FSL-NaB group (ANOVA, *p* = 0.039; FSL-Veh vs. FSL-NaB, Fisher's LSD, post-hoc *p* = 0.014; [Figure 2C](#F2){ref-type="fig"}). However, this difference did not reach significance when measuring the protein levels of DNMT1 (ANOVA, *p* = 0.84; FSL-Veh vs. FSL-NaB, Fisher's LSD, post-hoc *p* = 0.46; [Figure 2D](#F2){ref-type="fig"}).

###### 

Gene expression levels of *Tet* and *Dnmt* mRNAs were measured in the prefrontal cortex of Veh- and NaB-treated FSL and FRL animals using qRT-PCR. Differences found on the mRNA levels were also tested on the protein levels using the Western blot. (A) Only *Tet1* mRNA was differentially expressed between FRL-Veh and FSL-Veh, with reduced levels in the FSL. NaB treatment significantly increased *Tet1* mRNA expression in the FSL-NaB group. (B) TET1 protein levels were also reduced in FSL-Veh and were "rescued" in the FSL-NaB animals. (C) Even though *Dnmt1* mRNA levels were reduced in the FSL-NaB group, (D) protein measurements of DNMT1 did not reach a statistically significant level of difference. Gene expression data are presented as relative quantifications (R.Q.); two reference genes (*Gapdh* and *Ppia*) were used for normalization. Protein data are presented as % of FRL-Veh. Lower panels in (B) and (D) show representative Western blot images of TET1 and DNMT1 from the same gel, respectively, with β-actin as loading control. For each panel (B) and (D), the Western blot images were from the same gel. Data are presented as group means ± SEM. For all figures: n = 5--7 animals per group; n = 1 FSL-Veh outlier excluded. (A) n = 1 FSL-NaB outlier excluded. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001.
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TET1 Levels Correlate Positively with DNA Hydroxymethylation Levels at *BDNF* {#s12}
-----------------------------------------------------------------------------

The aberrant levels of TET1 in the prefrontal cortex of FSL-Veh suggested putative changes in DNA hydroxymethylation. However, the assessment of global (genome-wide) 5hmC levels revealed no differences between groups (ANOVA, *p* = 0.12; [Figure 3A](#F3){ref-type="fig"}). This led us to test the hypothesis that TET1 may affect specific genes. Among the list of candidate genes, we decided to study *Bdnf* since it is both associated with depression's pathophysiology and is affected by brain levels of TET1 ([@CIT0026]; [@CIT0031]). In line with our data showing a TET1 downregulation in FSL-Veh, we found a significant reduction in 5hmC levels at the *Bdnf* P4 locus in this group (ANOVA, *p* = 0.039; FSL-Veh vs. FRL-Veh, Fisher's LSD, post hoc *p* = 0.032; [Figure 3B](#F3){ref-type="fig"}). Interestingly, we also found that the NaB-dependent TET1 overexpression in FSL was associated with higher 5hmC levels at *Bdnf* P4 (FSL-Veh vs. FSL-NaB, Fisher's LSD, post-hoc *p* = 0.0059; [Figure 3B](#F3){ref-type="fig"}). Next, since hydroxymethylation is considered a mediator of active demethylation in the adult brain ([@CIT0026]), we also examined the levels of 5mC at the same *Bdnf* locus. In accord with the decreased 5hmC levels in FSL-Veh, the same group was hypermethylated at *Bdnf* P4 compared to FRL-Veh (ANOVA, *p* = 0.023; FSL-Veh vs. FRL-Veh, Fisher's LSD, post-hoc *p* = 0.025; [Figure 3B](#F3){ref-type="fig"}). Additionally, the NaB-dependent increase in 5hmC levels in *Bdnf* P4 of FSL was associated with DNA hypomethylation at the same locus (FSL-Veh vs. FSL-NaB, Fisher's LSD, post-hoc *p* = 0.0035; [Figure 3B](#F3){ref-type="fig"}). Finally, this inverse relationship between 5hmC and 5mC levels at the *Bdnf* P4 promoter was supported by a correlation analysis (*p* = 0.045, correlation coefficient = -0.48, [Figure 3C](#F3){ref-type="fig"}).

###### 

DNA hydroxymethylation (5hmC) and methylation (5mC) analyses were performed in the prefrontal cortex of Veh- and NaB-treated FRL and FSL animals. (A) Global 5hmC level was measured using ELISA and showed no significant changes between any of the groups. Data are presented as the average percent of the genomic DNA cytosines that are hydroxymethylated at the 5^th^ carbon. (B) Region-specific 5hmC and 5mC levels were measured at the *Bdnf* promoter 4 (P4) region, spanning the transcription start site, and data are presented as relative values. FSL-Veh animals had a significant reduction in 5hmC levels at the *Bdnf* P4 region, and NaB treatment was associated with increased 5hmC levels in the FSL-NaB group. In contrast, 5mC levels at the same locus showed an inverse pattern compared to 5hmC levels, with hypermethylation in FSL-Veh but hypomethylation in the FSL-NaB group. (C) Pearson's correlation analysis supported an inverse relationship between 5hmC and 5mC level at the *Bdnf* P4 locus (rho = -0.48; *p* = 0.045). Data in A and B are presented as group means ± SEM. n = 4--6 animals per group; n = 1 FSL-Veh outlier excluded. \**p* \< 0.05, \*\**p* \< 0.01.
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DNA Hydroxymethylation Is Associated with BDNF Expression {#s13}
---------------------------------------------------------

TET1-driven DNA hydroxymethylation is emerging as a marker of gene activation ([@CIT0026]). In order to examine this relationship, we measured mRNA levels of the *Bdnf* P4 isoform. Indeed, FSL-Veh rats that were found to have lower TET1 and 5hmC levels had downregulated levels of the *Bdnf* P4 transcript in the prefrontal cortex (ANOVA, *p* = 0.0064; FSL-Veh vs. FRL-Veh, Fisher's LSD, post-hoc *p* = 0.0012; [Figure 4A](#F4){ref-type="fig"}). In addition, NaB-dependent increase in TET1 and 5hmC levels in the FSL group was associated with a *Bdnf* P4 overexpression (FSL-Veh vs. FSL-NaB, Fisher's LSD, post hoc *p* = 0.014; [Figure 4A](#F4){ref-type="fig"}). Since previous studies ([@CIT0071]; [@CIT0016]; [@CIT0017]) have shown a positive correlation between P4-driven *Bdnf* mRNA levels and the expression of total *Bdnf* mRNA levels, we also wanted to test this finding in our model. In agreement with the latter studies, measurements of total *Bdnf* levels in our samples revealed similar expression patterns as with BDNF P4 (ANOVA, *p* \< 0.001; FSL-Veh vs. FRL-Veh, Fisher's LSD, post hoc *p* = 0.045; FSL-Veh vs. FSL-NaB, Fisher's LSD, post hoc *p* = 0.014; [Figure 4A](#F4){ref-type="fig"}). Finally, the differences of total BDNF mRNA were confirmed on the protein levels (ANOVA, *p* = 0.021; FSL-Veh vs. FRL-Veh, Fisher's LSD, post-hoc *p* = 0.017; FSL-Veh vs. FSL-NaB, Fisher's LSD, post-hoc *p* = 0.012; [Figure 4B](#F4){ref-type="fig"}). These data suggest that the P4 promoter of *Bdnf* contributes substantially to the levels of total *Bdnf* in the prefrontal cortex.

###### 

The expression of *Bdnf* P4 and total *Bdnf* mRNA levels were measured in the prefrontal cortex of Veh- and NaB-treated FRL and FSL animals using qRT-PCR; BDNF protein levels were tested using the Western blot. (A) While *Bdnf* P4 was downregulated in the FSL-Veh, NaB treatment increased *Bdnf* P4 levels in the FSL-NaB group. (B) This expression pattern was similar to the 5hmC level pattern at the *Bdnf* P4 locus. Total *Bdnf* exhibited a similar expression pattern as the *Bdnf* P4--driven expression. BDNF protein levels were also reduced in FSL-Veh and were "rescued" in the FSL-NaB animals. Gene expression data are presented as relative quantifications (R.Q.); two reference genes (*Gapdh* and *Ppia*) were used for normalization. Protein data are presented as % of FRL-Veh. The lower panel in (B) shows representative Western blot images of BDNF from the same gel with β-actin as loading control. All data represent group means ± SEM. n = 5--7 animals per group; n = 1 FRL-NaB outlier excluded in mRNA analysis. \**p* \< 0.05, \*\**p* \< 0.01.
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Discussion {#s14}
==========

General Points {#s15}
--------------

The epigenetic regulation of the genome refers to a number of mechanisms and modifications that occur at the level of DNA, RNA, histones, and chromatin remodeling complexes. Among these epigenetic modifications, histone acetylation and DNA methylation are the most extensively studied processes that have also been associated with psychopathology ([@CIT0068]). Histone acetylation occurs at lysine residues on their amino-terminal tails and, when acetylated, the positive charge of lysine is eliminated. This decreases the histones' affinity to the negatively-charged DNA, which is thought to lead to a chromatin loosening that gives access to regulatory proteins that increase transcriptional activity ([@CIT0064]). Histone deacetylases are enzymes that can remove these histone acetyl-groups, allowing the DNA to wrap the histones more tightly and thus repress transcription. Of note, there are already drugs (e.g., SAHA) that act by inhibiting histone deacetylation and are used as therapeutic agents against cancer. However, during recent years, HDACis have also received increased attention due to their putative efficacy in the therapy of psychiatric disorders ([@CIT0024]; [@CIT0045]). NaB belongs to the aforementioned class of epigenetic agents, with an established role in the inhibition of most class I and II histone deacetylases ([@CIT0009]; [@CIT0061]). While the majority of studies have utilized NaB for its HDACi properties and examined downstream acetylation changes, reports have also indicated an additional role for NaB in affecting DNA methylation ([@CIT0014]; [@CIT0014]; [@CIT0012]; [@CIT0004]; [@CIT0005]; [@CIT0010]; [@CIT0003]; [@CIT0059]; [@CIT0063]). NaB was also found to affect DNA methylation in a cell type--specific manner. Specifically, while NaB incubation of HeLa cells (cells with a cervical origin) resulted in DNA hypermethylation, incubation of glioblastoma cells (cells with a brain origin) resulted in DNA hypomethylation ([@CIT0012]). In line with the NaB demethylating data, studies using the HDACi valproic acid (VPA) also showed decreased methylation of tumor suppressor genes in neuroblastoma ([@CIT0025]) and of other specific genes in HEK 293 cells ([@CIT0015]; [@CIT0046]). Importantly, the VPA demethylating activity was shown to be DNA replication-independent ([@CIT0015]), which is relevant for studies using postmitotic tissue like the prefrontal cortex. DNA methylation surrounding transcriptional start sites has generally been coupled to gene silencing ([@CIT0008]), and aberrant DNA methylation changes have been associated with psychiatric disorders, including depression ([@CIT0033]). DNA methylation, once thought to be a rather permanent modification of cytosine residues, was recently found to be reversible through the action of TET-family enzymes. TETs can oxidize methylated cytosines to produce hydroxymethylated residues and, through this process, 5mC can either be passively reverted to unmethylated cytosine through DNA replication or it can be actively depleted through additional oxidation and thymine DNA glycosylase-mediated base excision repair ([@CIT0034]). The latter mechanism has important implications for studies of postmitotic tissues where cell division and DNA replication have ceased; as is often the case for neurons. In addition, 5hmC has been found to be most abundant in the brain, where it is particularly enriched in active genes, indicating a crucial role for this DNA modification in neuronal gene expression and memory formation ([@CIT0044]; [@CIT0031]).

Sodium Butyrate's Antidepressant-Like Effects are Associated with Increased Levels of TET1 in the Prefrontal Cortex {#s16}
-------------------------------------------------------------------------------------------------------------------

We hypothesized that part of NaB's antidepressant-like properties may involve changes on the DNA methylation level. We chose to work with the FSL rat line, which is an established genetic model of depression that has been successfully used for the past 25 years in depression-like and antidepressant-related studies ([@CIT0050]; [@CIT0049]). The first key finding was that NaB exerted a clear antidepressant-like effect in the FSL, in accord with previous behavioral data from NaB studies in mice ([@CIT0060]). Next, we examined whether NaB affected the expression of key enzymes regulating DNA methylation (*Dnmt1* and *Dnmt3a*) and hydroxymethylation (*Tet1, Tet2,* and *Tet3*) in the prefrontal cortex, a critical region implicated in the pathophysiology of depression ([@CIT0062]). We found that TET1 was the only enzyme that differed between vehicle-treated FSL and controls, and that it was also affected by NaB treatment. Specifically, FSL-Veh had decreased *Tet1* mRNA levels and, following NaB treatment, these levels were restored to normal, a finding that was also confirmed on the protein level. The treatment-related TET1 upregulation may be the consequence of a NaB-mediated increase in histone acetylation at *Tet1*, a finding that warrants future investigation. On the other hand, the TET1 difference between FSL-Veh and controls may be related to nucleotide variations, given that the FSL is a genetic model. In line with this assumption, we recently found that the FSL harbors a functional nucleotide polymorphism in the promoter of the neuropeptide Y (*Npy*) gene, which affects *Npy*'s transcriptional activity ([@CIT0042]). However, one limitation that needs to be acknowledged at this point is related to the pharmacological intervention. Specifically, the chronically i.p.-administered injections could represent a chronic stress paradigm that needs to be taken into consideration when interpreting the present report's results.

TET1 Upregulation is Associated with Increased Hydroxymethylation and Gene-Expression Levels of *Bdnf* {#s17}
------------------------------------------------------------------------------------------------------

The second part of our molecular analyses focused on a specific gene, the *Bdnf*, which has been repeatedly associated with depression ([@CIT0002]). We found that the decreased levels of TET1 in FSL-Veh were associated with decreased levels both of 5hmC in the *Bdnf* P4 promoter and of *Bdnf* P4 mRNA levels. Interestingly, the NaB-associated upregulation of TET1 led to an increase in both 5hmC and *Bdnf* mRNA levels. These findings are in line with two recent studies showing that TET1 overexpression in the mouse hippocampus also leads to increased *Bdnf* expression ([@CIT0026]; [@CIT0031]). Next, we also analyzed the 5mC levels at the same *Bdnf* locus and convincingly found a reversed pattern. More specifically, increased levels of 5mC were found in the FSL-Veh group, which had reduced TET1 and 5hmC levels, whereas lower levels of 5mC were present in the NaB-treated FSL group, which had higher TET1 and 5hmC levels. The latter group also had decreased *Dnmt1* mRNA levels, but we were not able to replicate this finding on the protein level. Nonetheless, it is worth mentioning that BDNF P4 was shown to be regulated by DNMT1 in cortical mouse neurons ([@CIT0041]) and treatment with DNMT inhibitors was found to increase *Bdnf* levels in the rat hippocampus ([@CIT0058]). Taken together, our analyses of modified cytosines at the *Bdnf* locus provide evidence that HDACi-associated upregulation of TET1 in the prefrontal cortex leads to increased 5mC to 5hmC conversion, which may reflect active DNA demethylation. However, it is noteworthy that the changes in TET1 levels were not associated with changes in global 5hmC levels. TET1 has been found to be present in both the nucleus and the soma of neurons, and also in the soma of astrocytes ([@CIT0031]). This could imply that the global effect of TET1 on the nuclear 5hmC levels can be buffered"by the TET1 localization in regions other than the nucleus. Thus, the ability of other studies to detect global 5hmC changes may be due to the employment of more drastic (e.g., viral-mediated) methodologies for TET1 overexpression ([@CIT0026]; [@CIT0031]). Finally, one should also keep in mind that while only two, and not six, comparisons were of main interest (FSL-Veh vs FRL-Veh and FSL-Veh vs FSL-NaB), Fisher's LSD was selected as the post-hoc test; this test does not provide an adequate correction for multiple comparisons. Also, the present data derive from the PFC of male rats only and, thus, both regional and gender differences need to be addressed in the future. For example, studies using female FSL have showed that certain selective serotonin reuptake inhibitors (e.g., escitalopram) lead to decreased expression of BDNF in the hippocampus ([@CIT0027]).

Clinical Relevance {#s18}
------------------

Our preclinical study adds to the growing evidence suggesting that epigenetic-acting agents such as HDAC inhibitors (e.g., NaB, SAHA, and MS275) and DNMT inhibitors (e.g., 5-AzaC) have potential antidepressant properties ([@CIT0060]; [@CIT0013]; [@CIT0074]; [@CIT0058]; [@CIT0070]; [@CIT0073]). The HDAC-dependent regulation of *Bdnf* P4 has repeatedly been supported by studies using HDACis, like NaB and VPA, both of which exert a positive effect on BDNF P4 transcription ([@CIT0069]; [@CIT0007]). Recently, another preclinical study showed that treatment with a different HDACi (CI-994) ameliorated anxiety-related phenotypes ([@CIT0023]). Anxiety disorders show high comorbidity with depression and have also been repeatedly associated with reduced levels of BDNF ([@CIT0065]). In addition, both depression and anxiety often co-occur with substance use disorders. This high co-occurrence has often been explained in terms of self-medication, with the patient using drugs in an attempt to reduce anxiety ([@CIT0057]). Interestingly, drugs like alcohol, cocaine, and nicotine have all been associated with a decrease in HDAC activity ([@CIT0036]; [@CIT0051]; [@CIT0037]). However, one should keep in mind that there are four major classes of HDACs with different members in each class, and some members (class II) have the ability to shuttle between the nucleus and the cytoplasm. In addition, each member shows variability in cell-type distribution in the brain ([@CIT0067]). HDACis, like NaB, act by inhibiting a number of HDACs non-specifically. Therefore, it is very unlikely that the therapeutic-like effects of current HDACis lie within the regulation of single genes like *Tet1* and *Bdnf*; rather, they most probably depend on the varying contributions of HDAC members present within a specific cell population. Thus, there is not only a need for elucidating the role that each HDAC plays in psychopathology but also a need for the development of more specific inhibitors

Concluding Remarks {#s19}
------------------

In the present study we found depression-like states to be associated both with changes in levels of the TET1 demethylation-facilitating enzyme and with concomitant alterations in hydroxymethylation of *Bdnf*. The molecular aberrations in these genes were found to be reversible with the use of an epigenetic targeting drug. These preclinical data obviously represent an oversimplified picture of the underpinnings of major depressive disorder in humans, and may perhaps relate to certain endophenotypes of the disorder. It has been recognized that most neuropsychiatric disorders, including depression, are not the result of mutations in a single gene but represent the outcome of molecular disturbances with low effect sizes in multiple genetic loci that are part of distinct regulatory pathways ([@CIT0030]). This also explains why the testing of single-target agents has mostly proven ineffective in psychopharmacological trials. Therefore, the trend has shifted towards the development of multi-target drugs for treating complex disorders ([@CIT0025]). The latter concept in drug design is also supported by findings showing that many genes are part of co-expression networks, meaning that their expression covaries ([@CIT0048]). A recent study in substance use disorders identified epigenetic modifications as being determinant factors of gene co-expression associated with alcoholism ([@CIT0054]). This implies that certain epigenetic marks may regulate a number of disorder-associated genes in a similar manner. Thus, pinpointing these aberrant epigenetic mechanisms and their target genes may lead to the discovery of novel multi-target epigenetic therapeutics with increased antidepressant efficacies.
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